Antibodies specific for ungulate PrP

Details Antibodies specific for ungulate PrP Antibodies specific for ungulate PrP

2000-07-27

2003-03-25

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S009100, C424S185100, C435S007100, C435S070100, C435S071100, C530S387100, C530S398000

Reexamination Certificate

active

06537548

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to antibodies, methods for obtaining antibodies and assays for using such antibodies. More specifically, the invention relates to ungulate PrP antibodies methods of obtaining antibodies which specifically bind to naturally occurring forms of PrP from ungulates.
BACKGROUND OF THE INVENTION
Prions are infectious pathogens that cause central nervous system spongiform encephalopathies in humans and animals. Prions are distinct from bacteria, viruses and viroids. The predominant hypothesis at present is that no nucleic acid component is necessary for infectivity of prion protein. Further, a prion which infects one species of animal (e.g., a human) will not readily infect another (e.g., a mouse).
A major step in the study of prions and the diseases that they cause was the discovery and purification of a protein designated prion protein (“PrP”) (Bolton et al. (1982),
Science
218:1309-11; Prusiner et al. (1982),
Biochemistry
21:6942-50; McKinley et al.(1983),
Cell
35:57-62). Complete prion protein-encoding genes have since been cloned, sequenced and expressed in transgenic animals. PrP
C
is encoded by a single-copy host gene (Basler et al.(1986),
Cell
46:417-28) and is normally found at the outer surface of neurons. A leading hypothesis is that prion diseases result from conversion of PrP
C
into a modified form called PrP
Sc
.
It appears that PrP
Sc
is necessary for both the transmission and pathogenesis of the transmissible neurodegenerative diseases of animals and humans. See Prusiner, S. B.(1991),
Science
252:1515-1522. The most common prion diseases of animals are scrapie of sheep and goats, and bovine spongiform encephalopathy (BSE) of cattle (Wilesmith, J. and Wells (1991),
Microbiol. Immunol.
172:21-38). Four prion diseases of humans have been identified: (1) kuru, (2) Creutzfeldt-Jakob Disease (CJD), (3) Gerstmann-Strassler-Scheinker Disease (GSS), and (4) fatal familial insomnia (FFI) (Gajdusek, D. C., (1977)
Science
197:943-960; Medori et al.(1992),
N. Engl. J. Med.
326:444-449). The presentation of human prion diseases as sporadic, genetic and infectious illnesses initially posed a conundrum which has been explained by the cellular genetic origin of PrP.
BSE is also a major socioeconomic problem, particularly in Britain. More than 175,000 cattle, primarily dairy cows, have died of BSE during the past decades. Tests conducted by the British government on cattle killed over a 30 month period suggest that about 0.3% of the 749,631 tested, or 2249 cattle may have had BSE even though they did not display any outward symptoms. On Mar. 27, 1996, the European Union (EU) placed a ban on the export of British bovine products, including: live bovine animals, their semen and embryos; meat of bovine animals slaughtered in UK; products obtained from bovine animals slaughtered in UK which are liable to enter the animal feed or human food chain; materials destined for use in medicinal products, cosmetics or pharmaceutical products; and mammalian derived meat and bone-meal. This ban has cost the British farming industry more than 1.5 billion pounds since it was imposed, and left many farmers bankrupt. Although the ban was lifted Aug. 1, 1999, both France and Germany still ban the import of British bovine products, contrary to the EU ruling.
The importance of detecting BSE has been heightened by the possibility that bovine prions have been transmitted to humans who developed new variant Creutzfeldt-Jakob disease (nvCJD) (G. Chazot et al.(1996),
Lancet
347:1181; R. G. Will et al. (1996),
Lancet
347:921-925). Earlier studies had shown that the N-terminus of PrP
Sc
could be truncated without loss of scrapie infectivity (S. B. Prusiner et al.(1982),
Biochemistry
21:6942-6950; S. B. Prusiner et al. (1984),
Cell
38:127-134) and correspondingly, the truncation of the N-terminus of PrP
Sc
still allowed its conversion into PrP
Sc
(M. Rogers et al.(1993),
Proc. Natl. Acad. Sci. USA
90:3182-3186). The ability of transmission of nvCJD from cattle to humans has been confirmed through in vivo testing, suggesting that the December 20 issue of Proceedings of National Academy of Sciences undermining the comforting presumption that the documented “species barrier” is relevant to this new strain (M. R. Scott et al. (1999),
Proc. Natl. Acad. Sci. USA
96:15137-15142).
The presence of PrP
Sc
in tissues of humans or animals is indicative of prion infection. PrP
Sc
is the invariant component of prion infection and is the only disease-specific diagnostic marker that can be readily detected by immunoassay in the brains of clinically ill animals and humans Meyer et al. (1986),
Proc. Natl. Acad. Sci. USA,
83:3693-7; Serban et al. (1990),
Neurology,
40:110-117; Taraboulos et al. (1992),
Proc. Natl. Acad. Sci. USA.
89:7620-7624; Grathwohl, K. U. D., M. Horiuchi et al. (1997),
Virol. Methods
64:205-216. Unfortunately, PrP
Sc
assays are positive only when the prion titer is high, while detection of low levels of PrP
Sc
has been problematic. It has also proven difficult to measure low levels of PrP
Sc
in the presence of high levels of PrP
C
.
Given the enormity of the potential effect of BSE on the world wide cattle population and the affected cattle population in Great Britain, there is a great need for a method of assessing bovine infection with BSE to protect the cattle populations. Given the potential health risk to the human population, more sensitive methods for detection of bovine prions are urgently needed.
SUMMARY OF THE INVENTION
The present invention provides antibodies that will specifically bind with a high degree of affinity to a native ungulate PrP
C
and/or a denatured ungulate PrP
Sc
, but not to a native ungulate PrP
Sc
. The antibodies are also highly specific, i.e. do not bind to other proteins. The antibodies are useful in numerous applications, and particularly for determining prion infection in ungulates. The antibodies are characterized by one or more of the following features (1) an ability to bind to native PrP
C
and denatured PrP
Sc
, but not native PrP
Sc
, with specificity, (2) an ability to bind to PrP
C
or denatured PrP
Sc
in situ i.e., will only bind to PrP
Sc
in a cell culture or in vivo if the prion protein has been treated (e.g. denatured). Preferred antibodies are further characterized by an ability to (4) bind to a PrP
C
protein of only a specific species of mammals e.g., bind to bovine PrP
C
and not to PrP
C
of other mammals.
An important object is to provide antibodies which bind to a native form of ungulate PrP
C
.
Another object is to provide antibodies which specifically bind to epitopes of PrP
C
of a specific species of animal (e.g. bovine PrP
C
) and not to the PrP
C
of other species of animals (e.g. mouse PrP
C
).
Still another object is to provide specific methodology to allow others to generate a wide range of specific antibodies characterized by their ability to bind one or more types of PrP
C
proteins from one or more species of ungulates.
Another object of the invention is to provide an assay for the detection of PrP
Sc
in an ungulate using the antibodies of the invention.
An advantage of the invention is that it provides a fast, efficient cost effective assay for detecting the presence of PrP
Sc
in an ungulate sample.
A specific advantage is that the assay can be used as a screen for the presence of prions (i.e., PrP
Sc
) in products such as pharmaceuticals (derived from natural sources) food, cosmetics or any material which might contain such prions and thereby provide further assurances as to the safety of such products.
Another advantage is that the antibodies can be used with a compound which denatures PrP
Sc
thereby providing for a means of differentiating levels of PrP
C
and PrP
C
+PrP
Sc
in a sample.
A feature of the invention is that it uses phage display libraries in the creation of the antibodies.
Another feature of the invention is that the phage are genetically engineered to express a specific binding protein of an antibody on their surface.
An aspec

Affiliated with

Also associated with

Rating

Antibodies specific for ungulate PrP does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies specific for ungulate PrP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specific for ungulate PrP will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3042871